WuXi AppTec Forecasts 103% Boost in 2025 Profit

MT Newswires Live

01/12

WuXi AppTec (HKG:2359) expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.

The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2602708512"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602708512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602708512?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602708512","market":"fut","top_or_hot":-1,"title":"WuXi AppTec Forecasts 103% Boost in 2025 Profit","media":"MT Newswires Live","content":"<html><body><p> WuXi AppTec (HKG:2359) expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.</p><p>The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi AppTec Forecasts 103% Boost in 2025 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi AppTec Forecasts 103% Boost in 2025 Profit\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-12 20:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> WuXi AppTec (HKG:2359) expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.</p><p>The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320764599.SGD","symbol_name":"FTIF - Templeton China A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2602708512","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602708512","pubTimestamp":1768221300,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"WuXi AppTec  expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1141":"生命科学工具和服务","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","02359":"药明康德","BK1583":"高瓴概念","BK1576":"医药外包概念","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc"},"translate_title":"药明康德预测2025年利润增长103%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"WuXi AppTec (HKG:2359) expects a net attributable profit of 19.2 billion yuan for the year 2025, up 103% from 9.45 billion yuan a year prior, according to a Monday Hong Kong bourse filing.The drug research company attributed the forecast to an investment gain from the sale of interest in WuXi XDC Cayman, as well as enhanced capabilities and capacity, optimized production processes, and improved operating efficiency.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}